General American Investors Co. Inc. Has $16.68 Million Holdings in Danaher Co. (NYSE:DHR)

General American Investors Co. Inc. grew its position in shares of Danaher Co. (NYSE:DHR - Free Report) by 20.0% in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 60,010 shares of the conglomerate's stock after buying an additional 10,000 shares during the quarter. General American Investors Co. Inc.'s holdings in Danaher were worth $16,684,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in the company. Benjamin Edwards Inc. raised its position in Danaher by 1.8% in the second quarter. Benjamin Edwards Inc. now owns 2,153 shares of the conglomerate's stock worth $538,000 after acquiring an additional 38 shares in the last quarter. Wedge Capital Management L L P NC boosted its holdings in Danaher by 3.2% during the third quarter. Wedge Capital Management L L P NC now owns 1,231 shares of the conglomerate's stock worth $342,000 after buying an additional 38 shares in the last quarter. Patrick M Sweeney & Associates Inc. grew its position in Danaher by 3.4% in the second quarter. Patrick M Sweeney & Associates Inc. now owns 1,230 shares of the conglomerate's stock worth $307,000 after buying an additional 40 shares during the last quarter. Trust Co of Kansas increased its holdings in shares of Danaher by 4.1% in the second quarter. Trust Co of Kansas now owns 1,022 shares of the conglomerate's stock valued at $255,000 after buying an additional 40 shares in the last quarter. Finally, Abacus Planning Group Inc. lifted its holdings in shares of Danaher by 0.7% during the second quarter. Abacus Planning Group Inc. now owns 5,439 shares of the conglomerate's stock valued at $1,359,000 after purchasing an additional 40 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company's stock.

Danaher Stock Performance

Shares of DHR stock traded down $1.66 during trading on Thursday, reaching $246.10. The company had a trading volume of 2,518,359 shares, compared to its average volume of 2,743,171. The company has a market capitalization of $177.75 billion, a PE ratio of 47.06, a PEG ratio of 4.54 and a beta of 0.85. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. The firm's 50 day simple moving average is $265.79 and its two-hundred day simple moving average is $260.75. Danaher Co. has a one year low of $192.35 and a one year high of $281.70.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping analysts' consensus estimates of $1.57 by $0.14. The business had revenue of $5.80 billion during the quarter, compared to analysts' expectations of $5.59 billion. Danaher had a net margin of 16.39% and a return on equity of 10.62%. Danaher's revenue for the quarter was up 3.1% on a year-over-year basis. During the same period in the previous year, the company earned $2.02 earnings per share. Sell-side analysts forecast that Danaher Co. will post 7.51 earnings per share for the current year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, October 25th. Stockholders of record on Friday, September 27th were given a $0.27 dividend. The ex-dividend date of this dividend was Friday, September 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.44%. Danaher's dividend payout ratio is 20.61%.

Insiders Place Their Bets

In related news, SVP Georgeann Couchara sold 952 shares of the stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares in the company, valued at approximately $1,130,374.44. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 10.90% of the company's stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on DHR. Stifel Nicolaus lifted their target price on shares of Danaher from $250.00 to $265.00 and gave the stock a "hold" rating in a research report on Wednesday, October 23rd. UBS Group decreased their price objective on shares of Danaher from $309.00 to $305.00 and set a "buy" rating for the company in a research note on Wednesday, October 23rd. The Goldman Sachs Group boosted their target price on shares of Danaher from $225.00 to $250.00 and gave the company a "neutral" rating in a research note on Wednesday, July 24th. Stephens reaffirmed an "overweight" rating and issued a $315.00 target price on shares of Danaher in a research report on Wednesday, October 23rd. Finally, Evercore ISI upped their price target on Danaher from $275.00 to $278.00 and gave the company an "outperform" rating in a research report on Tuesday, October 1st. Five research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $287.16.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.